We are developing functional human insulin-producing pancreatic islet cells (beta cells) for therapeutic uses, including in particular for diabetes patients, with a particular focus on type 1 diabetes. We are developing these specialized human cells (beta cells) from induced pluripotent stem cells (iPSCs).

We have developed a novel 3-stage method for dorsal pancreatic progenitors which is used to generate these insulin-producing cells. This small molecule-only based method results in significant reduction in production costs of these cells compared to current standards.

We are also developing an automated solution to scale the production of these cells.